Biotech RadarJobs updated

COMPANY

Design Therapeutics

HQ: Carlsbad, CA source · designtx.com ↗ · West Coast

Clinical Phase 2

Keywords: small molecule Friedreich ataxia fuchs endothelial corneal dystrophy myotonic dystrophy friedreich's ataxia DT-216P2 DT-216 DT-168

Location: Carlsbad, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

5Trials (company is sponsor)1NIH grants

Timeline

  1. Trial start Phase 2: DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy source ↗
  2. Trial start Phase 1/Phase 2: A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia source ↗
  3. Trial start Phase 1: A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants source ↗
  4. Trial start Phase 1: Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia source ↗
  5. Trial start Phase 1: Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 5

RecordTitlePhaseStatusStartPrimary completion
NCT07024693DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal DystrophyPhase 2RecruitingJul 30, 20252027-12 (estimated)
NCT06874010A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's AtaxiaPhase 1/Phase 2Recruiting2025-062026-12 (estimated)
NCT06772870A Single Ascending Dose Study of DT-216P2 in Normal Healthy ParticipantsPhase 1Not yet recruiting2025-022025-09 (estimated)
NCT05573698Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich AtaxiaPhase 1CompletedSep 27, 2022Aug 25, 2023 (actual)
NCT05285540Study to Evaluate DT-216 in Adult Patients With Friedreich AtaxiaPhase 1CompletedMar 11, 2022Dec 19, 2022 (actual)

NIH awards 1

Annual award amounts. Total $435K.

Feedback